Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy G1 Therapeutics stock
Own G1 Therapeutics stock in just a few minutes.
G1 Therapeutics, Inc is a biotechnology business based in the US. G1 Therapeutics shares (GTHX) are listed on the NASDAQ and all prices are listed in US Dollars. G1 Therapeutics employs 122 staff and has a trailing 12-month revenue of around USD$45.3 million.
How to buy shares in G1 Therapeutics
- Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
- Search for G1 Therapeutics. Find the stock by name or ticker symbol: GTHX. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until G1 Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of G1 Therapeutics, depending on your broker.
- Check in on your investment. Congratulations, you own a part of G1 Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
G1 Therapeutics share price
Use our graph to track the performance of GTHX stocks over time.G1 Therapeutics shares at a glance
Information last updated 2021-04-08.
| 52-week range | USD$10.81 - USD$37.069 |
|---|---|
| 50-day moving average | USD$23.256 |
| 200-day moving average | USD$18.7998 |
| Wall St. target price | USD$59 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | USD$-2.703 |
Buy G1 Therapeutics shares from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy G1 Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
G1 Therapeutics financials
| Revenue TTM | USD$45.3 million |
|---|---|
| Gross profit TTM | USD$45.3 million |
| Return on assets TTM | -23.49% |
| Return on equity TTM | -45.86% |
| Profit margin | -219.18% |
| Book value | $4.653 |
| Market capitalisation | USD$1.1 billion |
TTM: trailing 12 months
Shorting G1 Therapeutics shares
There are currently 7.7 million G1 Therapeutics shares held short by investors – that's known as G1 Therapeutics's "short interest". This figure is 21% up from 6.3 million last month.
There are a few different ways that this level of interest in shorting G1 Therapeutics shares can be evaluated.
G1 Therapeutics's "short interest ratio" (SIR)
G1 Therapeutics's "short interest ratio" (SIR) is the quantity of G1 Therapeutics shares currently shorted divided by the average quantity of G1 Therapeutics shares traded daily (recently around 2.2 million). G1 Therapeutics's SIR currently stands at 3.45. In other words for every 100,000 G1 Therapeutics shares traded daily on the market, roughly 3450 shares are currently held short.
However G1 Therapeutics's short interest can also be evaluated against the total number of G1 Therapeutics shares, or, against the total number of tradable G1 Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case G1 Therapeutics's short interest could be expressed as 0.18% of the outstanding shares (for every 100,000 G1 Therapeutics shares in existence, roughly 180 shares are currently held short) or 0.2816% of the tradable shares (for every 100,000 tradable G1 Therapeutics shares, roughly 282 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against G1 Therapeutics.
Find out more about how you can short G1 Therapeutics stock.
G1 Therapeutics share dividends
We're not expecting G1 Therapeutics to pay a dividend over the next 12 months.
G1 Therapeutics share price volatility
Over the last 12 months, G1 Therapeutics's shares have ranged in value from as little as $10.81 up to $37.069. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while G1 Therapeutics's is 2.3272. This would suggest that G1 Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
G1 Therapeutics overview
G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase III clinical trials for patients with first line colorectal cancer, as well as Phase II clinical trials for the treatment of neoadjuvant breast cancer; lerociclib, an oral CDK4/6 inhibitor for multiple oncology indications; and rintodestrant, an oral selective estrogen receptor degrader, which is in Phase IIa clinical trials for the treatment of estrogen receptor-positive and HER2-negative breast cancer. The company has a collaboration with Quantum Leap Healthcare Collaborative to evaluate trilaciclib for neoadjuvant treatment of locally advanced breast cancer; and license agreement with EQRx, Inc. and Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat any indication in humans, as well as Nanjing Simcere Dongyuan Pharmaceutical Co., LTD. for the development and commercialization of trilaciclib for any indication in humans through parenteral delivery, and ARC Therapeutics for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses. G1 Therapeutics, Inc. was founded in 2008 and is headquartered in Research Triangle Park, North Carolina.
Frequently asked questions
More guides on Finder
-
How to buy Sigma Labs stock
Steps to owning and managing SGLB, with 24-hour and historical pricing before you buy.
-
How to buy Simpson Manufacturing CoInc stock
Steps to owning and managing SSD, with 24-hour and historical pricing before you buy.
-
How to buy Sequans Communications S-A stock
Steps to owning and managing SQNS, with 24-hour and historical pricing before you buy.
-
How to buy SFL Corporation stock
Steps to owning and managing SFL, with 24-hour and historical pricing before you buy.
-
How to buy Senmiao Technology stock
Steps to owning and managing AIHS, with 24-hour and historical pricing before you buy.
-
How to buy Sensata Technologies Holding stock
Steps to owning and managing ST, with 24-hour and historical pricing before you buy.
-
How to buy Select Bancorp stock
Steps to owning and managing SLCT, with 24-hour and historical pricing before you buy.
-
How to buy Second Sight Medical Products stock
Steps to owning and managing EYES, with 24-hour and historical pricing before you buy.
-
How to buy Sibanye Stillwater stock
Steps to owning and managing SBSW, with 24-hour and historical pricing before you buy.
-
How to buy Shinhan Financial Group CoLtd stock
Steps to owning and managing SHG, with 24-hour and historical pricing before you buy.
Ask an Expert